About ABRAXANE ® ABRAXANE ® is an albumin-bound form of paclitaxel that is manufactured using patented nab ® technology. ABRAXANE is formulated with albumin, a human protein, and is free of solvents. The most common adverse reactions (≥ 20%) with a ≥ 5% higher incidence in the ABRAXANE/gemcitabine treatment group are neutropenia, fatigue, peripheral neuropathy, nausea, alopecia, peripheral edema, diarrhea, pyrexia, vomiting, decreased appetite, rash, and dehydration. 4
Please refer to the ABRAXANE product monograph for complete safety information.
ABRAXANE in combination with gemcitabine for the treatment of metastatic pancreatic cancer is approved in
the United States and 30 other countries, including
Australia as well as countries in
About Celgene Celgene Corporation is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's website at www.celgene.com.
All trademarks used or mentioned in this release are protected by law.
___________________________ 1 Von Hoff DD, Ervin T, Arena FP, et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. New England Journal of Medicine. 2013; 369(18):1691-703. 2 Canadian Cancer Society, Statistics Canada, Public Health Agency of Canada. Canadian Cancer Statistics 2014. Special topic: Skin cancers. Available at: http://www.cancer.ca/~/media/cancer.ca/CW/publications/Canadian%20Cancer%20Statistics%202014/Canadian-Cancer-Statistics-2014-EN.pdf Accessed August 5, 2014. 3 Canadian Cancer Society. Malignant tumours of the pancreas. Available at: http://www.cancer.ca/en/cancer-information/cancer-type/pancreatic/pathology-and-staging/malignant-tumours/?region=on Accessed August 5, 2014. 4 ABRAXANE ® Product Monograph. July 15, 2014. Celgene Corporation.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV